Patient engagement has become an increasingly important factor in the pharmaceutical industry, influencing various aspects of drug development, marketing, post-market surveillance, risk management, investor perception, cost savings, and regulatory and payer engagement.
Clinical Trials and Drug Development:
- Engaging with patients can provide insights into what patients truly need, leading to the development of drugs that are more aligned with patient preferences and needs.
- Patient input can help design clinical trials that are more patient-friendly, potentially increasing enrollment and retention rates.
- Drugs developed with patient input might face fewer regulatory hurdles as they address real-world needs and concerns.
Market Potential and Demand:
- Engaging with patients can help pharmaceutical companies identify unmet needs in the market, leading to the development of innovative drugs with high demand.
- Companies that actively engage with patients and address their concerns can build brand loyalty, leading to sustained sales and revenue.
Post-market Surveillance:
- Engaging with patients post-market can provide real-world data on drug efficacy and side effects, which can be invaluable for future drug development and marketing strategies.
- Active patient engagement can lead to faster reporting of adverse events, allowing companies to address safety concerns promptly.
Risk Management:
- Companies that actively engage with patients and address their concerns are less likely to face reputational risks.
- Companies can mitigate potential legal risks associated with adverse events or unmet expectations by understanding patient concerns and addressing them proactively.
Investor Perception:
- Companies that prioritize patient engagement are often viewed positively by investors, as they are seen as forward-thinking and patient-centric. Investors increasingly recognize the value of patient engagement and are more likely to invest in companies that prioritize it.
- Engaging with patients can lead to sustainable growth by ensuring that drugs are developed based on real-world needs and demands.
Cost Savings:
- By understanding patient needs early on, companies can focus their research and development (R&D) efforts more efficiently, potentially leading to cost savings.
- Drugs developed based on patient input might require less marketing effort as they address real-world needs.
Regulatory and Payer Engagement:
- Engaging with patients can help companies build a strong value proposition for regulators and payers, leading to faster approvals and better reimbursement rates.
Case 1: Pfizer
Pfizer is a great example in the pharmaceutical industry that prioritizes patient engagement. Pfizer focuses on patients throughout the drug development process. The company collaborates with patients and advocates to develop treatments and innovative approaches to address patient challenges.
- Patient-Centric Approach: Pfizer’s primary goal is to create breakthroughs that significantly impact patients’ lives from the initial stages of drug development to the final approval and use of their medicines and vaccines.
- Collaboration: Pfizer actively collaborates with patients, advocates, and caregivers to address the evolving needs of patients everywhere. This collaboration extends to various facets, including R&D, clinical trials, and patient support programs.
- Pfizer has a patient engagement lead based in every region, which ensures it can work with all patients and advocates, irrespective of their location, disease focus, or economic status.
- Diverse Clinical Trials: One of Pfizer’s initiatives is diversifying clinical trials; this ensures that the trials are more representative and can address a broader range of patient needs.
- Educational Materials and Support Programs: Pfizer develops patient-friendly educational materials and support programs. These resources are designed to empower patients and provide the necessary information and support for their treatments.
- Feedback and Improvement: Pfizer values feedback from the global patient community. The company continuously seeks insights on enhancing its patient engagement efforts and providing better support.
- Pfizer established its Global Patient Advocacy team, which leads the enterprise-wide strategy to collaborate with patient advocacy groups. The team’s primary goal is to contribute to the company’s end-to-end advocacy strategy and drive deep therapeutic and regional relationship models with patient advocacy groups, as well as the focus and outcomes of Pfizer’s innovations. The team aims to create and nurture sustainable partnerships that improve patient outcomes.
Case 2: Eli Lilly
Eli Lilly, a global pharmaceutical company, has various initiatives related to patient engagement that could influence investor perception.
- Patient Engagement and Adherence Workshop: Eli Lilly provides a series of modules and resources focused on patient engagement and adherence. These modules cover topics such as decoding medical jargon, using plain language with patients, the Ask Me 3 and Teach-Back Method, person-centered communication skills using open questions, affirming, reflective listening, summarizing (OARS), and creating a clear communication action plan. The resources aim to enhance patient understanding, engagement, and adherence to medical advice and treatments.
- Commitment to Health Equity: In May 2021, Eli Lilly announced a commitment of US$5 million to Direct Relief’s Fund for Health Equity over the next five years. This fund was launched in March 2020 and aims to address health disparities and promote health equity.
- In January 2021, Eli Lilly participated in the 39th Annual J.P. Morgan Healthcare Conference. David A. Ricks, Lilly’s chairman and chief executive officer, took part in a virtual fireside chat during the conference. Such participation in major healthcare conferences can influence investor perception by showcasing the company’s latest developments and plans.
As the healthcare landscape continues to evolve, patient engagement will likely play an even more significant role in shaping the pharmaceutical industry’s future. Should you have any questions, please get in touch with the Fundopedia team or consult your Fundopedia advisor.